Eastern Cooperative Oncology Group

描述（由申请人提供）：约翰霍普金斯大学自1955年以来一直是ECOG的成员。我们的主要目标是将约翰霍普金斯大学试点的创新临床研究方案和实验室相关科学带到集团进一步发展。与此同时，我们的教师担任研究主席和实验室联合主席，疾病和模式导向委员会主席的领导角色。具体目标是：1)继续在以疾病为导向的委员会中提供科学领导：乳房，胸部，头颈，泌尿生殖系统，脑肿瘤工作组，淋巴瘤，白血病；2)继续扩大我们在疾病和模式委员会的参与：胃肠道、骨髓瘤、药理学和药物开发；将相关转化研究、细胞生物学和分子生物学纳入疾病各个阶段的临床方案；4)继续扩大应计收益，并在数据质量上保持优异的表现。这些目标将通过约翰霍普金斯大学Sidney Kimmel综合癌症中心的使命来实现：为癌症研究提供多学科方法，从而改进预防、诊断和治疗手段。该中心在转化研究方面取得了卓越的成就，获得了七项SPORE资助（宫颈癌，淋巴瘤，G-l癌，前列腺癌，乳腺癌，肺癌，头颈部）。此外，新药的早期临床试验是根据NCI一期合同进行的（自1982年以来）。早期治疗发展与第二阶段重点拨款允许开发新的第二和第三阶段的概念，癌症中心的教师带来ECOG与适当的实验室科学相关的研究。中心设施的扩展允许开发新的临床项目，招募新的教师，进一步加强委员会的参与和临床试验的积累。

DESCRIPTION (provided by applicant): Johns Hopkins has been a member of ECOG since 1955. Our primary goal is to bring innovative clinical research protocols and laboratory correlative science piloted at Johns Hopkins to the Group for further development. In conjunction with this, our faculty serve in leadership roles as study chairs and laboratory co-chairs, disease and modality-oriented committee chairs. The specific aims are: 1) to continue to provide scientific leadership in the disease-oriented committees: Breast, Thoracic, Head and Neck, Genitourinary, Brain Tumor Working Group, Lymphoma, Leukemia; 2) to continue to expand our involvement in the disease and modality committees: Gastrointestinal, Myeloma, Pharmacology and Drug Development; to bring translational research correlates, cell biology and molecular biology into clinical protocols for all stages of disease; 4) to continue to expand accrual, and to maintain excellent performance in data quality. These goals will be accomplished through the mission of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins: to provide a multidisciplinary approach to the study of cancer that will result in improved means for prevention, diagnosis, and treatment. The Center has achieved excellence in translational research with the awarding of seven SPORE grants (cervix, lymphoma, G-l cancer, prostate, breast, lung, head and neck). In addition, early clinical trials of new drugs are conducted under the NCI phase I contract (since 1982). The Early Therapeutics Development with Phase II Emphasis grants allow the development of novel phase II and phase III concepts which the Cancer Center faculty bring to ECOG with appropriate laboratory science correlative studies. The expansion of Center facilities allows the development of new clinical prograins, the recruitment of new faculty, furthering committee involvement and clinical trial accrual. RELEVANCE: Johns Hopkins has an extraordinary institutional commitment to the health of the public. Through close collaboration, the Cancer Center and the School of Public Health advance the study of not only cancer treatments, but also the early detection, screening, prevention of cancer, and its effect on financial stability and quality of life, thus encompassing the overall impact of cancer on the lives of patients.